Literature DB >> 8197160

A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

J D Burton1, R N Bamford, C Peters, A J Grant, G Kurys, C K Goldman, J Brennan, E Roessler, T A Waldmann.   

Abstract

In early phases of human T-cell lymphotrophic virus I-induced adult T-cell leukemia (ATL), the malignant cell proliferation is associated with an autocrine process involving coordinate expression of interleukin (IL) 2 and its receptor. However, during late-phase ATL, leukemic cells no longer produce IL-2 yet continue to express high-affinity IL-2 receptors. During studies to define pathogenic mechanisms that underlie this IL-2-independent proliferation, we demonstrated that the ATL cell line HuT-102 secretes a lymphokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Conditioned medium from HuT-102, when added to the IL-2-dependent CTLL-2 line, yielded a stimulation index of 230. Since CTLL-2 was purported to be IL-2-specific, we performed a number of studies to exclude IL-2 production by HuT-102. Stimulation of CTLL-2 cells by HuT-102-conditioned medium was not meaningfully inhibited by addition of an antiserum to IL-2. Furthermore, uninduced HuT-102 cells did not express mRNA encoding IL-2 as assessed by Northern blot analysis. No biological activity on CTLL-2 cells was mediated by purified IL-1, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-13, or granulocyte/macrophage colony-stimulating factor, thus differentiating these factors from IL-T. Based on preliminary biochemical data, IL-T is a protein with a pI value of 4.5 and a molecular mass in SDS gels of 14 kDa. In addition to its action on CTLL-2 cells, 3200-fold-purified IL-T stimulated proliferation of the human cytokine-dependent T-cell line Kit-225. Furthermore, addition of IL-T enhanced cytotoxic activity of large granular lymphocytes (i.e., induced lymphokine-activated killer cells). Thus, IL-T is a lymphokine that plays a role in T-cell proliferation and induction of lymphokine-activated killer cells. Furthermore, IL-T may contribute to IL-2-independent proliferation of select ATL cells and lines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8197160      PMCID: PMC43904          DOI: 10.1073/pnas.91.11.4935

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  Cytokines in T-cell development.

Authors:  S R Carding; A C Hayday; K Bottomly
Journal:  Immunol Today       Date:  1991-07

Review 2.  The interleukin-2 receptor.

Authors:  T A Waldmann
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

Review 3.  T-cell growth factor.

Authors:  K A Smith
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

4.  Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases.

Authors:  J C Vernant; L Maurs; A Gessain; F Barin; O Gout; J M Delaporte; K Sanhadji; G Buisson; G de-Thé
Journal:  Ann Neurol       Date:  1987-02       Impact factor: 10.422

5.  Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.

Authors:  A J Grant; R E Merchant; R E Hall
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

6.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  R N Bamford; A J Grant; J D Burton; C Peters; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

7.  A biochemical variant of human T cell growth factor produced by a cutaneous T cell lymphoma cell line.

Authors:  J E Gootenberg; F W Ruscetti; R C Gallo
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

8.  Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Authors:  C L Tendler; S J Greenberg; W A Blattner; A Manns; E Murphy; T Fleisher; B Hanchard; O Morgan; J D Burton; D L Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.

Authors:  H Schorle; T Holtschke; T Hünig; A Schimpl; I Horak
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

View more
  98 in total

1.  IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory.

Authors:  Patrick R Burkett; Rima Koka; Marcia Chien; Sophia Chai; Faye Chan; Averil Ma; David L Boone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

2.  Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.

Authors:  Vinay V Vyas; Dominic Esposito; Terry L Sumpter; Trevor L Broadt; James Hartley; George C Knapp; Wei Cheng; Man-Shiow Jiang; John M Roach; Xiaoyi Yang; Steven L Giardina; George Mitra; Jason L Yovandich; Stephen P Creekmore; Thomas A Waldmann; Jianwei Zhu
Journal:  Biotechnol Prog       Date:  2011-12-09

3.  Interleukin-15 strongly inhibits interleukin-8 and monocyte chemoattractant protein-1 production in human colonic epithelial cells.

Authors:  N Lügering; T Kucharzik; C Maaser; M Kraft; W Domschke
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

4.  Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges.

Authors:  Chalet Tan; Thomas A Waldmann
Journal:  Expert Opin Drug Deliv       Date:  2020-05-19       Impact factor: 6.648

5.  Interleukin-15 enhances proliferation and chemokine secretion of human follicular dendritic cells.

Authors:  Minchan Gil; Seo-Jeong Park; Yoo-Sam Chung; Chan-Sik Park
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 6.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Authors:  Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2005-02       Impact factor: 16.687

7.  Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Authors:  Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

8.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

9.  Effect of IL-15 and natural killer cells on osteoclasts and osteoblasts in a mouse coculture.

Authors:  Hiroaki Takeda; Takeshi Kikuchi; Kyoko Soboku; Iichiro Okabe; Hiroki Mizutani; Akio Mitani; Yuichi Ishihara; Toshihide Noguchi
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

10.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.